An observational study in Colorectal Neoplasms Malignant, sponsored by Wageningen University. Active, not recruiting at 11 sites in Netherlands. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Wageningen University · Observational
The main aim of this observational, prospective cohort study is to assess associations of diet and other lifestyle factors with colorectal cancer recurrence, survival and quality of life.
The COLON study is a multi-centre prospective cohort study among incident colorectal cancer patients recruited from 12 hospitals in the Netherlands. Patients with colorectal cancer are invited upon diagnosis. Upon recruitment, after 6 months, 2 years and 5 years, patients fill out food-frequency questionnaires; questionnaires about dietary supplement use, physical activity, weight, height, and quality of life; and donate blood samples. Diagnostic CT-scans are collected to assess cross-sectional areas of skeletal muscle, subcutaneous fat, visceral fat and intermuscular fat, and to assess muscle attenuation. Blood samples are biobanked to facilitate future analyse of biomarkers, nutrients, DNA etc. Analysis of serum 25-hydroxy vitamin D levels, B-vitamins and metabolomic profiles are scheduled. A subgroup of patients with colon cancer is asked to provide faecal samples before and at several time points after colon resection to study changes in gut microbiota during treatment. For all patients, information on vital status is retrieved by linkage with national registries. Information on clinical characteristics, including treatment-related toxicity and co-morbidity data, is gathered from linkage with the Netherlands Cancer Registry and with hospital databases or medical records. Hazard ratios will be calculated for dietary and lifestyle factors at diagnosis in relation to recurrence and survival. Repeated measures analyses will be performed to assess changes over time in dietary and other factors in relation to recurrence and survival.
The aim is to recruit at least 2000 patients with available data and blood samples.
5,598 studies on the registry are indexed under Colorectal Neoplasms; 1,458 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Wageningen University is the lead sponsor of 150 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Men and women of all ages, who were newly diagnosed with colorectal cancer (ICD codes C18-20) in any stage of the disease in one of the participating hospitals.
Exclusion Criteria:
Other: No intervention: observational study
Survival
Overall survival
Time frame: An average follow-up of at least 5 years
Cancer recurrence
Cancer recurrence
Time frame: An average follow-up of at least 5 years
Quality of life (EORTC QLQ-C30)
Quality of life
Time frame: An average follow-up of at least 5 years
Chemotherapy-induced toxicity (QLQ-CIPN20)
Chemotherapy-induced peripheral neuropathy
Time frame: 12 months after diagnosis
Microbiota composition based on 16S rRNA profiling
Stool samples
Time frame: At diagnosis and 6, 12 and 35 weeks after resection
Co-morbidities
Time frame: An average follow-up of at least 5 years
Plan to share: No
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wageningen University